Examestane in advanced or recurrent endometrial carcinoma: A prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)

We evaluated the efficacy and safety of the aromatase inhibitor exemestane in patients with advanced, persistent or recurrent endometrial carcinoma. Methods: We performed an open-label one-arm, two-stage, phase II study of 25 mg of oral exemestane in 51 patients with advanced (FIGO stage III-IV) or relapsed endometrioid endometrial cancer.